{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:12:03Z","timestamp":1785913923456,"version":"3.56.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CVC Capital Partners and Philanthrophy"},{"name":"Deutscher Akademischer Austauschdienst"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118246","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:38:33Z","timestamp":1750394313000},"page":"118246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identification of nsp16 inhibitors of SARS -CoV-2, SARS -CoV-1 and MERS-CoV from FDA-approved drugs using in silico and in vitro methods"],"prefix":"10.1016","volume":"189","author":[{"given":"Ejlal A.","family":"Omer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abdelfatah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Shahhamzehei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Guthart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-6555","authenticated-orcid":false,"given":"Hannah S.","family":"Schwarzer-Sperber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-5180","authenticated-orcid":false,"given":"Roland","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5016-2696","authenticated-orcid":false,"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118246_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature20167","article-title":"Redefining the invertebrate RNA virosphere","volume":"540","author":"Shi","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118246_bib2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.rceng.2023.02.010","article-title":"What do we know about the origin of COVID-19 three years later?","volume":"223","author":"Zapatero Gaviria","year":"2023","journal-title":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)"},{"key":"10.1016\/j.biopha.2025.118246_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.biopha.2025.118246_bib4","unstructured":"WHO Coronavirus (COVID-19) Dashboard, (n.d.). \u3008https:\/\/covid19.who.int\u3009 (accessed September 21, 2023)."},{"key":"10.1016\/j.biopha.2025.118246_bib5","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2025.118246_bib6","first-page":"1","article-title":"SARS-CoV-2 biology and host interactions","author":"Steiner","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2025.118246_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13337-020-00632-9","article-title":"SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations","volume":"31","author":"Krishnamoorthy","year":"2020","journal-title":"VirusDis"},{"key":"10.1016\/j.biopha.2025.118246_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.aivir.2016.08.008","article-title":"The nonstructural proteins directing coronavirus RNA synthesis and processing","volume":"96","author":"Snijder","year":"2016","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.biopha.2025.118246_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eng.2018.11.035","article-title":"Molecular Characteristics, functions, and related pathogenicity of MERS-CoV proteins","volume":"5","author":"Li","year":"2019","journal-title":"Engineering"},{"key":"10.1016\/j.biopha.2025.118246_bib10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.sbi.2005.10.004","article-title":"Structural insights into SARS coronavirus proteins","volume":"15","author":"Bartlam","year":"2005","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.biopha.2025.118246_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.virusres.2014.10.008","article-title":"Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus","volume":"194","author":"Sevajol","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2025.118246_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.virusres.2014.09.009","article-title":"Coronavirus non-structural protein 16: Evasion, attenuation, and possible treatments","volume":"194","author":"Menachery","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2025.118246_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199211","article-title":"Coronavirus 2\u2032-O-methyltransferase: a promising therapeutic target","volume":"336","author":"Schindewolf","year":"2023","journal-title":"Virus Res"},{"key":"10.1016\/j.biopha.2025.118246_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12967-023-03996-w","article-title":"Global landscape of SARS-CoV-2 mutations and conserved regions","volume":"21","author":"Abbasian","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118246_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature09489","article-title":"2\u2032-O methylation of the viral mRNA cap evades host restriction by IFIT family members","volume":"468","author":"Daffis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118246_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2675","article-title":"Conventional and unconventional mechanisms for capping viral mRNA","volume":"10","author":"Decroly","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2025.118246_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00346-17","article-title":"Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis","volume":"2","author":"Menachery","year":"2017","journal-title":"MSphere"},{"key":"10.1016\/j.biopha.2025.118246_bib18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/molecules28030988","article-title":"Coronavirus inhibitors targeting nsp16","volume":"28","author":"Omer","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118246_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118246_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100713","article-title":"Repurposing old drugs to fight multidrug resistant cancers","volume":"52","author":"Dini\u0107","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.biopha.2025.118246_bib21","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1038\/s41467-021-23328-0","article-title":"Drug repurposing screens identify chemical entities for the development of COVID-19 interventions","volume":"12","author":"Bakowski","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118246_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1358\/dnp.2010.23.1.1440373","article-title":"The Year\u2019s New Drugs & Biologics - 2009","volume":"23","author":"Graul","year":"2010","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.biopha.2025.118246_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.biopha.2025.118246_bib24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ajic.2020.07.031","article-title":"Susceptibility of SARS-CoV-2 to UV irradiation","volume":"48","author":"Heilingloh","year":"2020","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.biopha.2025.118246_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573526","article-title":"A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyze neutralizing antibodies and antiviral compounds","volume":"11","author":"Sch\u00f6ler","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118246_bib26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/ph15030308","article-title":"In silico and in vitro identification of pan-coronaviral main protease inhibitors from a large natural product library","volume":"15","author":"Shahhamzehei","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118246_bib27","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2025.118246_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.biopha.2025.118246_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105246","article-title":"Human coronaviruses: origin, host and receptor","volume":"155","author":"Tang","year":"2022","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.biopha.2025.118246_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s12276-021-00604-z","article-title":"On the origin and evolution of SARS-CoV-2","volume":"53","author":"Singh","year":"2021","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.biopha.2025.118246_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2025.118246_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01532-22","article-title":"SARS-CoV-2 uses nonstructural protein 16 to evade restriction by IFIT1 and IFIT3","volume":"97","author":"Schindewolf","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2025.118246_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105360","article-title":"Conserved coronavirus proteins as targets of broad-spectrum antivirals","volume":"204","author":"Melo-Filho","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2025.118246_bib34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/v13040538","article-title":"NSP16 2\u2032-O-MTase in coronavirus pathogenesis: possible prevention and treatments strategies","volume":"13","author":"Chang","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118246_bib35","article-title":"SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential","author":"Vithani","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2025.118246_bib36","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1021\/acsinfecdis.3c00203","article-title":"Discovery of a druggable, cryptic pocket in SARS-CoV-2 nsp16 using allosteric inhibitors","volume":"9","author":"Inniss","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118246_bib37","article-title":"SS148 and WZ16 inhibit the activities of nsp10-nsp16 complexes from all seven human pathogenic coronaviruses","volume":"1867","author":"Li","year":"2023","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"key":"10.1016\/j.biopha.2025.118246_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153310","article-title":"Caffeic acid derivatives (CAFDs) as inhibitors of SARS-CoV-2: CAFDs-based functional foods as a potential alternative approach to combat COVID-19","volume":"85","author":"Adem","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2025.118246_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129706","article-title":"An ascidian Polycarpa aurata-derived pan-inhibitor against coronaviruses targeting Mpro","volume":"103","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2025.118246_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154942","article-title":"Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion","volume":"118","author":"Gao","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2025.118246_bib41","article-title":"Gossypol broadly inhibits coronaviruses by targeting RNA-dependent RNA polymerases","volume":"9","author":"Wang","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2025.118246_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-01758-8","article-title":"Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1","volume":"9","author":"Xie","year":"2024","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.118246_bib43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ymthe.2023.11.019","article-title":"A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion","volume":"32","author":"Feng","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2025.118246_bib44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41467-023-44504-4","article-title":"Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1","volume":"15","author":"Khan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118246_bib45","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/ph15091046","article-title":"Potential coronaviral inhibitors of the nucleocapsid protein identified in silico and in vitro from a large natural product library","volume":"15","author":"Pohler","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118246_bib46","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/09298673113209990001","article-title":"Virtual screening strategies in drug discovery: a critical review","volume":"20","author":"Lavecchia","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118246_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104359","article-title":"Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning","volume":"133","author":"Kadioglu","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.biopha.2025.118246_bib48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/24725552211008863","article-title":"A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex","volume":"26","author":"Khalili Yazdi","year":"2021","journal-title":"Slas Discovery: Advancing Science Drug Discovery"},{"key":"10.1016\/j.biopha.2025.118246_bib49","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/2472555220985040","article-title":"A high-throughput RNA displacement assay for screening SARS-CoV-2 nsp10-nsp16 complex toward developing therapeutics for COVID-19","volume":"26","author":"Perveen","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.biopha.2025.118246_bib50","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1177\/24725552211026261","article-title":"Probing the SAM binding site of SARS-CoV-2 Nsp14 in vitro using SAM competitive inhibitors guides developing selective bisubstrate inhibitors","volume":"26","author":"Devkota","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.biopha.2025.118246_bib51","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/acsinfecdis.1c00131","article-title":"The structure-based design of SARS-CoV-2 nsp14 methyltransferase ligands yields nanomolar inhibitors","volume":"7","author":"Otava","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118246_bib52","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acsmedchemlett.1c00140","article-title":"Potent SARS-CoV-2 mRNA cap methyltransferase inhibitors by bioisosteric replacement of methionine in SAM cosubstrate","volume":"12","author":"Bobi\u013ceva","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2025.118246_bib53","article-title":"SARS-CoV-2 methyltransferase nsp10-16 in complex with natural and drug-like purine analogs for guiding structure-based drug discovery","volume":"13","author":"Kremling","year":"2024","journal-title":"ELife"},{"key":"10.1016\/j.biopha.2025.118246_bib54","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1021\/acs.jcim.1c00524","article-title":"Drug repurposing to identify nilotinib as a potential SARS-CoV-2 main protease inhibitor: insights from a computational and in vitro study","volume":"61","author":"Banerjee","year":"2021","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.biopha.2025.118246_bib55","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bcpt.13537","article-title":"The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro","volume":"128","author":"Cagno","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2025.118246_bib56","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2025.118246_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003500","article-title":"Productive replication of ebola virus is regulated by the c-Abl1 tyrosine kinase","volume":"4","author":"Garc\u00eda","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118246_bib58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/07391102.2020.1813200","article-title":"Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M pro","volume":"40","author":"D. Francis","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2025.118246_bib59","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1039\/D0NJ04909C","article-title":"Targeting Nsp9 as an anti-SARS-CoV-2 strategy","volume":"45","author":"Farias","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.biopha.2025.118246_bib60","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijmr.IJMR_1132_20","article-title":"Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: an: in silico: approach","volume":"153","author":"Behera","year":"2021","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.biopha.2025.118246_bib61","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1080\/07391102.2020.1796804","article-title":"Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2","volume":"39","author":"Ahmed","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2025.118246_bib62","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1021\/acscentsci.0c01186","article-title":"Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir","volume":"7","author":"Lo","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.biopha.2025.118246_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109133","article-title":"Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture","volume":"35","author":"Bafna","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2025.118246_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104419","article-title":"Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein","volume":"85","author":"Feng","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.biopha.2025.118246_bib65","unstructured":"A. Swargiary, A.K. Verma, M. Daimari, M.K. Roy, Simeprevir and eltrombopag as potential inhibitors of SARS-CoV2 proteases: a molecular docking and virtual screening approach to combat COVID-19, (n.d.)."},{"key":"10.1016\/j.biopha.2025.118246_bib66","first-page":"14","article-title":"An in silico investigation of allosteric inhibition potential of Dihydroergotamine against Sars-CoV-2 Main Protease (MPro)","volume":"7","author":"Ya\u015far","year":"2023","journal-title":"Turk. Comp. Theo Chem. (TCTC)"},{"key":"10.1016\/j.biopha.2025.118246_bib67","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1016\/j.sjbs.2020.06.005","article-title":"In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors","volume":"27","author":"Gurung","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118246_bib68","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.4014\/jmb.2009.09009","article-title":"Repurposing screens of FDA-approved drugs identify 29 inhibitors of SARS-CoV-2","volume":"30","author":"Ku","year":"2020","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.biopha.2025.118246_bib69","doi-asserted-by":"crossref","first-page":"43490","DOI":"10.1021\/acsomega.3c02921","article-title":"Targeting the spike: repurposing mithramycin and dihydroergotamine to block SARS-CoV-2 infection","volume":"8","author":"Stagnoli","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2025.118246_bib70","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40265-014-0341-2","article-title":"Simeprevir: a review of its use in patients with chronic Hepatitis C virus infection","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2025.118246_bib71","unstructured":"Olysio Prices, Coupons, Copay & Patient Assistance, Drugs.Com (n.d.). http:\/\/www.drugs.com\/price-guide\/olysio (accessed May 16, 2024)."},{"key":"10.1016\/j.biopha.2025.118246_bib72","unstructured":"Tasigna Prices, Coupons, Copay & Patient Assistance, Drugs.Com (n.d.). http:\/\/www.drugs.com\/price-guide\/tasigna (accessed May 16, 2024)."},{"key":"10.1016\/j.biopha.2025.118246_bib73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12927\/hcpap.2023.27000","article-title":"Expensive drugs for rare diseases in Canada: what value and at what cost?","volume":"21","author":"Sirrs","year":"2023","journal-title":"Health Pap."},{"key":"10.1016\/j.biopha.2025.118246_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:50:57Z","timestamp":1754653857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":74,"alternative-id":["S0753332225004408"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118246","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of nsp16 inhibitors of SARS -CoV-2, SARS -CoV-1 and MERS-CoV from FDA-approved drugs using in silico and in vitro methods","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118246"}}